The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Open accessAbstract
Purpose: To determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer. Patients and Methods: Data from Gynecologic Oncology Group protocols 114 and 172 were retrospectively analyzed. Cox proportional hazards regression models were used for statistical analyses. Results: In 876 patients, median follow-up was 10.7 years. Median survival with IP therapy was 61.8 months (95% CI, 55.5 to 69.5), compared with 51.4 months (95% CI, 46.0 to 58.2) for intravenous therapy. IP therapy was associated with a 23% decreased risk of death (adjusted hazard ratio [AHR], 0.77; 95% CI, 0.65 to 0.90; P = .002). IP therapy improved survival of those with gross residual (≤ 1 cm) disease (AHR, 0.75; 95% CI, 0.62 to 0.92; P = .006). Risk of death decreased by 12% for each cycle of IP chemotherapy completed (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Factors associated with poorer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to 4.24; P < .001), gross residual versus no visible disease (AHR, 1.89; 95% CI, 1.48 to 2.43; P < .001), and fewer versus more cycles of IP chemotherapy (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Younger patients were more likely to complete the IP regimen, with a 5% decrease in probability of completion with each year of age (odds ratio, 0.95; 95% CI, 0.93 to 0.96; P < .001). Conclusion: The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
On a Test of Whether one of Two Random Variables is Stochastically Larger than the Other
Mann, H. B., & Whitney, D. R. (1947) · The Annals of Mathematical Statistics · doi:10.1214/aoms/1177730491 · Cited by 14,320
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Pearson, K. (1900) · The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science · doi:10.1080/14786440009463897 · Cited by 4,069
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Self-citationWald, A. (1943) · Transactions of the American Mathematical Society · doi:10.1090/s0002-9947-1943-0012401-3 · Cited by 2,511
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Self-citationPharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Rl, D., Ce, M., Bungay, P. M., & Vt, D. (1978) · PubMed · Cited by 735
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Broglio, K. R., & Berry, D. A. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp369 · Cited by 491
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L., Rubin, S., Curtin, J., Barakat, R., & Phillips, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1485 · Cited by 313
Self-citationHowell, S. B., Zimm, S., Markman, M., Abramson, I. S., Cleary, S., Lucas, W. E., & Weiss, R. J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1607 · Cited by 221
Self-citationMcGuire, W. P., Hoskins, W. J., Brady, M. F., Homesley, H. D., Creasman, W. T., Berman, M. L., Ball, H., Berek, J. S., & Woodward, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1589 · Cited by 213
Los, G., Mutsaers, P. H. A., van der Vijgh, W. J. F., Baldew, G. S., de Graaf, P. W., & McVie, J. G. (1989) · PubMed · Cited by 205
Francis, P. A., Rowinsky, E. K., Schneider, J., Hakes, T. B., Hoskins, W. J., & Markman, M. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2961 · Cited by 191
Self-citationPatterns and Progress in Ovarian Cancer Over 14 Years
Chan, J. K., Cheung, M. K., Husain, A., Teng, N. N., West, D., Whittemore, A. S., Berek, J. S., & Osann, K. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000231680.58221.a7 · Cited by 163
Self-citationMcGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · PubMed · Cited by 150
Markman, M., Brady, M. F., Spirtos, N. M., Hanjani, P., & Rubin, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2620 · Cited by 143
Self-citationIntraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-Up
Barakat, R. R., Sabbatini, P. J., Bhaskaran, D., Revzin, M., Smith, A., Venkatraman, E., Aghajanian, C., Hensley, M. L., Soignet, S., Brown, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.694 · Cited by 116
Self-citationHess, L. M., Benham-Hutchins, M. M., Herzog, T. J., Hsu, C., Malone, D., Skrepnek, G., Slack, M., & Ds, A. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00846.x · Cited by 88
Self-citationChan, J. K. (2003) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(03)00399-5 · Cited by 83
Self-citationPharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.
Pretorius, R. G., Hacker, N. F., Berek, J. S., Ford, L. C., Hoeschele, J. D., Butler, T. A., & Lagasse, L. D. (1983) · PubMed · Cited by 65
Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma
Trimble, E. L., & Christian, M. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.006 · Cited by 48
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
van Driel, W. J., Koole, S. N., Sikorska, K., Schagen van Leeuwen, J. H., Schreuder, H. W. R., Hermans, R. H. M., de Hingh, I. H. J. T., van der Velden, J., Arts, H. J., Massuger, L. F. A. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1708618 · Cited by 1,426
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Metadata
- Authors
- Tewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-05-01
- Volume
- 33
- Issue
- 13
- Pages
- 1460-1466
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2152574852
- Cited by
- 288
- References
- 31
- FWCI
- 41.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.